

Selection of Hepatitis B Virus Polymerase Mutations in with Tenofovir

Antiviral Therapy

10, 727-734

DOI: [10.1177/135965350501000612](https://doi.org/10.1177/135965350501000612)

Citation Report

#	ARTICLE	IF	CITATIONS
2	Complications in treating chronic hepatitis B in patients with HIV. Expert Opinion on Pharmacotherapy, 2005, 6, 2831-2842.	0.9	2
6	Treatment of lamivudine-resistant hepatitis B in HIV-infected persons: Is adefovir dipivoxil the answer?. Journal of Hepatology, 2006, 44, 1-3.	1.8	10
7	HBV drug resistance: Mechanisms, detection and interpretation. Journal of Hepatology, 2006, 44, 593-606.	1.8	480
8	Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy. Aids, 2006, 20, 863-870.	1.0	159
9	Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection. Aids, 2006, 20, 1951-1954.	1.0	64
10	Hepatitis B virus drug resistance: mechanism and clinical implications for the prevention of treatment failure. Future Virology, 2006, 1, 361-376.	0.9	3
12	Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients. Hepatology, 2006, 43, 548-555.	3.6	149
13	Tenofovir disoproxil fumarate: Role in hepatitis B treatment. Hepatology, 2006, 44, 309-313.	3.6	27
14	Detection of rtN236T and rtA181V/T Mutations Associated with Resistance to Adefovir Dipivoxil in Samples from Patients with Chronic Hepatitis B Virus Infection by the INNO-LiPA HBV DR Line Probe Assay (Version 2). Journal of Clinical Microbiology, 2006, 44, 1994-1997.	1.8	62
15	Intracellular Metabolism and In Vitro Activity of Tenofovir against Hepatitis B Virus. Antimicrobial Agents and Chemotherapy, 2006, 50, 2471-2477.	1.4	221
16	Treatment of chronic hepatitis B: efficacy of current drugs and prospects for the future. Expert Review of Clinical Immunology, 2006, 2, 915-929.	1.3	0
17	Management of chronic hepatitis B and C in HIV-coinfected patients. Journal of Antimicrobial Chemotherapy, 2006, 57, 815-818.	1.3	78
18	In Vitro Activity of 2,4-Diamino-6-[2-(Phosphonomethoxy)Ethoxy]-Pyrimidine against Multidrug-Resistant Hepatitis B Virus Mutants. Antimicrobial Agents and Chemotherapy, 2007, 51, 2240-2243.	1.4	43
19	Safety and Tolerability of Sequential Pegylated IFN- α 2a and Tenofovir for Hepatitis B Infection in HIV+ Individuals. HIV Clinical Trials, 2007, 8, 173-181.	2.0	21
20	The management of HIV and hepatitis B coinfection. Current Opinion in Infectious Diseases, 2007, 20, 16-21.	1.3	15
21	Selection of Hepatitis B Virus (HBV) Vaccine Escape Mutants in HBV-Infected and HBV/HIV-Coinfected Patients Failing Antiretroviral Drugs With Anti-HBV Activity. Journal of Acquired Immune Deficiency Syndromes (1999), 2007, 46, 279-282.	0.9	54
22	Tenofovir disoproxil fumarate for the treatment of hepatitis B virus infection: pharmacokinetics and clinical efficacy. Therapy: Open Access in Clinical Medicine, 2007, 4, 141-151.	0.2	0
23	Hepatitis B virus genetic variability and evolution. Virus Research, 2007, 127, 164-176.	1.1	246

#	ARTICLE	IF	CITATIONS
24	Clinical implications of HIV and hepatitis B co-infection in Asia and Africa. <i>Lancet Infectious Diseases</i> , 2007, 7, 402-409.	4.6	285
25	Genotyping and Genomic Sequencing in Clinical Practice. <i>Clinics in Liver Disease</i> , 2007, 11, 761-795.	1.0	15
26	Understanding the Pathogenesis and Management of Hepatitis B/HIV and Hepatitis B/Hepatitis C Virus Coinfection. <i>Clinics in Liver Disease</i> , 2007, 11, 917-943.	1.0	19
27	Antiviral Therapy of Chronic Hepatitis B: Prevention of Drug Resistance. <i>Clinics in Liver Disease</i> , 2007, 11, 869-892.	1.0	36
28	Hepatitis B and End-Stage Liver Disease. <i>Clinics in Liver Disease</i> , 2007, 11, 893-916.	1.0	16
29	Drug Targets and Molecular Mechanisms of Drug Resistance in Chronic Hepatitis B. <i>Gastroenterology</i> , 2007, 132, 1574-1585.	0.6	154
30	Viral Hepatitis in HIV Infection. <i>New England Journal of Medicine</i> , 2007, 356, 1445-1454.	13.9	282
31	Management of Chronic Hepatitis B: Consensus Guidelines. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2007, 21, 5C-24C.	1.8	65
33	Antiviral drug-resistant HBV: Standardization of nomenclature and assays and recommendations for management. <i>Hepatology</i> , 2007, 46, 254-265.	3.6	418
34	Acyclic nucleoside phosphonates: Past, present and future. <i>Biochemical Pharmacology</i> , 2007, 73, 911-922.	2.0	139
36	Co-infection avec les hépatites virales. <i>Journal Africain D'Hepato-Gastroenterologie</i> , 2007, 1, 38-50.	0.0	1
37	Management of hepatitis B virus co-infection on and off antiretroviral therapy. <i>Current HIV/AIDS Reports</i> , 2008, 5, 86-93.	1.1	9
38	Evaluation and treatment of the patient coinfecting with hepatitis B and HIV. <i>Current HIV/AIDS Reports</i> , 2008, 5, 103-11.	1.1	3
39	Antiviral treatment of chronic hepatitis B virus infections: the past, the present and the future. <i>Reviews in Medical Virology</i> , 2008, 18, 19-34.	3.9	67
40	Current treatment of HIV/hepatitis B virus coinfection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008, 23, 699-706.	1.4	24
43	Drugs Treatment of Hepatitis B. <i>Farmacia Hospitalaria (English Edition)</i> , 2008, 32, 234-248.	0.0	0
44	Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations. <i>Journal of Hepatology</i> , 2008, 48, 391-398.	1.8	128
45	Potency of tenofovir in chronic hepatitis B: Mono or combination therapy?. <i>Journal of Hepatology</i> , 2008, 48, 383-386.	1.8	28

#	ARTICLE	IF	CITATIONS
46	Hepatitis B: Reflections on the current approach to antiviral therapy. <i>Journal of Hepatology</i> , 2008, 48, S2-S19.	1.8	142
47	Monitoring antiviral resistance in patients receiving nucleos(t)ide analog therapies for hepatitis B: Which method should be used?. <i>Journal of Hepatology</i> , 2008, 48, 892-894.	1.8	7
51	Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-Hepatitis B Virus International Panel. <i>Aids</i> , 2008, 22, 1399-1410.	1.0	149
52	Hepatitis B virus escape mutants induced by antiviral therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 61, 766-768.	1.3	115
53	Resistance issues in treating chronic hepatitis B. <i>Future Microbiology</i> , 2008, 3, 525-538.	1.0	19
54	Role of tenofovir in the treatment of chronic HBV infection. <i>Future Virology</i> , 2008, 3, 207-220.	0.9	4
55	Selection of an entecavir-resistant mutant despite prolonged hepatitis B virus DNA suppression, in a chronic hepatitis B patient with preexistent lamivudine resistance: successful rescue therapy with tenofovir. <i>European Journal of Gastroenterology and Hepatology</i> , 2008, 20, 773-777.	0.8	25
56	The implications of antiviral drugs with activity against hepatitis B virus and HIV. <i>Current Opinion in Internal Medicine</i> , 2008, 7, 57-64.	1.5	3
57	The Impact of Rapid Evolution of Hepatitis Viruses. , 2008, , 303-349.		11
58	Tenofovir and its potential in the treatment of hepatitis B virus. <i>Therapeutics and Clinical Risk Management</i> , 2009, 5, 177.	0.9	9
59	Safety and efficacy of telbivudine for the treatment of chronic hepatitis B. <i>Therapeutics and Clinical Risk Management</i> , 2009, 5, 789.	0.9	12
60	Pharmacotherapy of Chronic Hepatitis B in Adults: Focus on Tenofovir Disoproxil Fumarate. <i>Clinical Medicine Therapeutics</i> , 2009, 1, CMT.S1161.	0.1	0
61	New approaches in the management of chronic hepatitis B: role of tenofovir. <i>Infection and Drug Resistance</i> , 2009, 2, 13.	1.1	4
62	Anti-Hepatitis B Virus Activity in Vitro of Combinations of Tenofovir with Nucleoside/nucleotide Analogues. <i>Antiviral Chemistry and Chemotherapy</i> , 2009, 19, 165-176.	0.3	23
63	Ultra-Deep Pyrosequencing of Hepatitis B Virus Quasispecies from Nucleoside and Nucleotide Reverse Transcriptase Inhibitor (NRTI)-Treated Patients and NRTI-Naive Patients. <i>Journal of Infectious Diseases</i> , 2009, 199, 1275-1285.	1.9	195
64	Tenofovir for the Treatment of Hepatitis B Virus. <i>Pharmacotherapy</i> , 2009, 29, 1212-1227.	1.2	35
65	Telbivudine, a nucleoside analog inhibitor of HBV polymerase, has a different in vitro cross-resistance profile than the nucleotide analog inhibitors adefovir and tenofovir. <i>Antiviral Research</i> , 2009, 81, 147-155.	1.9	53
66	The rtA194T polymerase mutation impacts viral replication and susceptibility to tenofovir in hepatitis B e antigen-positive and hepatitis B e antigen-negative hepatitis B virus strains. <i>Hepatology</i> , 2009, 49, 1158-1165.	3.6	118

#	ARTICLE	IF	CITATIONS
67	Side effects of long-term oral antiviral therapy for hepatitis B. <i>Hepatology</i> , 2009, 49, S185-S195.	3.6	230
68	Chronic hepatitis B: Update 2009. <i>Hepatology</i> , 2009, 50, 661-662.	3.6	2,506
69	HIV and coinfecting patients. <i>Current Hepatitis Reports</i> , 2009, 8, 103-110.	0.3	0
70	Hepatitis B in HIV: Available treatment options and approach to therapy. <i>Current Infectious Disease Reports</i> , 2009, 11, 407-413.	1.3	1
71	Reduced glomerular filtration rate but sustained virologic response in HIV/hepatitis B coinfected individuals on long-term tenofovir. <i>Journal of Viral Hepatitis</i> , 2009, 16, 471-478.	1.0	18
72	Management and prevention of drug resistance in chronic hepatitis B. <i>Liver International</i> , 2009, 29, 108-115.	1.9	34
73	Prolonged use of tenofovir in HIV/hepatitis B virus (HBV) coinfected individuals does not lead to HBV polymerase mutations and is associated with persistence of lamivudine HBV polymerase mutations. <i>HIV Medicine</i> , 2009, 10, 229-235.	1.0	34
74	Long-term outcome of tenofovir disoproxil fumarate use against hepatitis B in an HIV coinfected cohort. <i>HIV Medicine</i> , 2009, 10, 269-273.	1.0	17
75	Sensitivity and accuracy of an updated line probe assay (HBV DR v.3) in detecting mutations associated with hepatitis B antiviral resistance. <i>Journal of Hepatology</i> , 2009, 50, 42-48.	1.8	46
76	Evolution of nucleoside/tide analogues for hepatitis B: Is the ideal drug here yet?. <i>Journal of Hepatology</i> , 2009, 51, 416-418.	1.8	5
77	Hepatitis B Virus Resistance to Nucleos(t)ide Analogues. <i>Gastroenterology</i> , 2009, 137, 1593-1608.e2.	0.6	614
78	Tenofovir Disoproxil Fumarate. <i>Drugs</i> , 2009, 69, 2245-2256.	4.9	25
79	Pathobiology of HBV mutants and clinical impact for treatment monitoring. <i>Expert Review of Anti-Infective Therapy</i> , 2009, 7, 309-320.	2.0	17
80	Short Communication: Transmission of Hepatitis B Viruses with Lamivudine Resistance Mutations in Newly Diagnosed HIV Individuals. <i>AIDS Research and Human Retroviruses</i> , 2009, 25, 1273-1276.	0.5	295
81	Prevention and management of drug resistance for antihepatitis B treatment. <i>Lancet Infectious Diseases</i> , The, 2009, 9, 256-264.	4.6	36
82	Molecular analysis of an HBsAg-negative hepatitis B virus mutant selected in a tenofovir-treated HIV-hepatitis B virus co-infected patient. <i>Aids</i> , 2009, 23, 268-272.	1.0	22
83	Combination HBV therapy is linked to greater HBV DNA suppression in a cohort of lamivudine-experienced HIV/HBV coinfected individuals. <i>Aids</i> , 2009, 23, 1707-1715.	1.0	50
84	Frequent hepatitis B virus rebound among HIV hepatitis B virus-coinfected patients following antiretroviral therapy interruption. <i>Aids</i> , 2010, 24, 857-865.	1.0	59

#	ARTICLE	IF	CITATIONS
85	Efficacy of tenofovir disoproxil fumarate/emtricitabine compared with emtricitabine alone in antiretroviral-naive HIV/HBV coinfection in Thailand. <i>Antiviral Therapy</i> , 2010, 15, 917-922.	0.6	29
86	Profile of HBV antiviral resistance mutations with distinct evolutionary pathways against nucleoside/nucleotide analogue treatment among Chinese chronic hepatitis B patients. <i>Antiviral Therapy</i> , 2010, 15, 1171-1178.	0.6	25
87	Effect of newer oral antiviral agents on future therapy of chronic hepatitis B. <i>Antiviral Therapy</i> , 2010, 15, 13-22.	0.6	7
88	The underlying mechanisms for the "anti-HBc alone"™ serological profile. <i>Archives of Virology</i> , 2010, 155, 149-158.	0.9	60
89	Molecular characterization of occult and overt hepatitis B (HBV) infection in an HIV-infected person with reactivation of HBV after antiretroviral treatment interruption. <i>Infection</i> , 2010, 38, 417-421.	2.3	13
91	Viral hepatitis and HIV co-infection. <i>Antiviral Research</i> , 2010, 85, 303-315.	1.9	177
92	Hepatitis B virus reverse transcriptase sequence variant database for sequence analysis and mutation discovery. <i>Antiviral Research</i> , 2010, 88, 269-275.	1.9	45
93	Drug Therapy: Tenofovir. <i>Hepatology</i> , 2010, 52, 743-747.	3.6	18
94	Virology and clinical sequelae of drug-resistant HBV in HIV-HBV-coinfected patients on highly active antiretroviral therapy. <i>Antiviral Therapy</i> , 2010, 15, 487-491.	0.6	6
95	Managing HBV in patients with impaired immunity. <i>Gut</i> , 2010, 59, 1430-1445.	6.1	63
96	Review: Efficacy and safety of tenofovir disoproxil fumarate in patients with chronic hepatitis B. <i>Therapeutic Advances in Gastroenterology</i> , 2010, 3, 107-119.	1.4	51
97	New paradigms for treating hepatitis B in HIV/hepatitis B virus co-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 379-382.	1.3	10
98	Comparison of the Mechanisms of Drug Resistance among HIV, Hepatitis B, and Hepatitis C. <i>Viruses</i> , 2010, 2, 2696-2739.	1.5	35
99	Antiviral Treatment of Chronic Hepatitis B Virus (HBV) Infections. <i>Viruses</i> , 2010, 2, 1279-1305.	1.5	56
100	Management of End-Stage Liver Disease in Chronic Hepatitis B. <i>Clinics in Liver Disease</i> , 2010, 14, 477-493.	1.0	3
101	Antiviral Drug Resistance: Mechanisms and Clinical Implications. <i>Infectious Disease Clinics of North America</i> , 2010, 24, 809-833.	1.9	71
102	Discovery and Development of Anti-HBV Agents and Their Resistance. <i>Molecules</i> , 2010, 15, 5878-5908.	1.7	48
103	Long-term Therapy With Tenofovir Is Effective for Patients Co-Infected With Human Immunodeficiency Virus and Hepatitis B Virus. <i>Gastroenterology</i> , 2010, 139, 1934-1941.	0.6	123

#	ARTICLE	IF	CITATIONS
104	Review of Hepatitis B Therapeutics. <i>Clinical Infectious Diseases</i> , 2010, 51, 1201-1208.	2.9	69
105	Monitoring of hepatitis B virus surface antigen escape mutations and concomitantly nucleos(t)ide analog resistance mutations in Turkish patients with chronic hepatitis B. <i>International Journal of Infectious Diseases</i> , 2010, 14, e136-e141.	1.5	34
106	Tenofovir disoproxil fumarate in the treatment of chronic hepatitis B. <i>Expert Review of Anti-Infective Therapy</i> , 2010, 8, 1079-1092.	2.0	15
107	Antiviral Drug Resistance: Mechanisms and Clinical Implications. <i>Infectious Disease Clinics of North America</i> , 2010, 24, 413-437.	1.9	161
108	Emerging pipeline drugs for hepatitis B infection. <i>Expert Opinion on Emerging Drugs</i> , 2011, 16, 713-729.	1.0	23
109	Three-Year Efficacy and Safety of Tenofovir Disoproxil Fumarate Treatment for Chronic Hepatitis B. <i>Gastroenterology</i> , 2011, 140, 132-143.	0.6	419
111	Hepatitis B virus drug resistance to current nucleos(t)ide analogs: Mechanisms and mutation sites. <i>Hepatology Research</i> , 2011, 41, 1017-1024.	1.8	26
112	Quasispecies Analysis and <i>In Vitro</i> Susceptibility of HBV Strains Isolated from HIV-1/HBV-Coinfected Patients with Delayed Response to Tenofovir. <i>Antiviral Therapy</i> , 2012, 17, 61-70.	0.6	15
113	Characterization of drug-resistance mutations in HBV D-genotype chronically infected patients, naïve to antiviral drugs. <i>Antiviral Research</i> , 2011, 92, 382-385.	1.9	19
114	Current Antiviral Therapy of Chronic Hepatitis B: Efficacy and Safety. <i>Current Hepatitis Reports</i> , 2011, 10, 235-243.	0.3	25
115	Unsuccessful therapy with adefovir and entecavir-tenofovir in a patient with chronic hepatitis B infection with previous resistance to lamivudine: a fourteen-year evolution of hepatitis B virus mutations. <i>BMC Infectious Diseases</i> , 2011, 11, 178.	1.3	8
116	Phylogenetic analysis of hepatitis B virus genotype F complete genome sequences from Chilean patients with chronic infection. <i>Journal of Medical Virology</i> , 2011, 83, 1530-1536.	2.5	22
117	No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus. <i>Hepatology</i> , 2011, 53, 763-773.	3.6	163
119	Republished paper: Managing HBV in patients with impaired immunity. <i>Postgraduate Medical Journal</i> , 2011, 87, 223-238.	0.9	3
120	Nucleoside/nucleotide analogues in the treatment of chronic hepatitis B. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 2715-2725.	1.3	168
121	Tenofovir in the treatment of chronic hepatitis B. <i>Therapy: Open Access in Clinical Medicine</i> , 2011, 8, 527-544.	0.2	1
122	Outbreak of Infections by Hepatitis B Virus Genotype A and Transmission of Genetic Drug Resistance in Patients Coinfected with HIV-1 in Japan. <i>Journal of Clinical Microbiology</i> , 2011, 49, 1017-1024.	1.8	41
123	The YMDD and rtA194T Mutations Result in Decreased Replication Capacity in Wild-Type HBV as well as in HBV with Precore and Basal Core Promoter Mutations. <i>Antiviral Chemistry and Chemotherapy</i> , 2011, 22, 13-22.	0.3	13

#	ARTICLE	IF	CITATIONS
124	Evolution of Adefovir-Resistant HBV Polymerase Gene Variants after Switching to Tenofovir Disoproxil Fumarate Monotherapy. <i>Antiviral Therapy</i> , 2012, 17, 1049-1058.	0.6	15
125	Selection of chronic hepatitis B therapy with high barrier to resistance. <i>Lancet Infectious Diseases</i> , 2012, 12, 341-353.	4.6	127
126	Emergence of cytomegalovirus resistance to foscarnet in a patient receiving foscarnet salvage therapy for multidrug-resistant HIV infection. <i>Journal of Clinical Virology</i> , 2012, 54, 194-196.	1.6	10
127	Tenofovir disoproxil fumarate in the treatment of chronic hepatitis B. <i>Expert Review of Gastroenterology and Hepatology</i> , 2012, 6, 413-421.	1.4	10
128	Management of Chronic Hepatitis B: Canadian Association for the Study of the Liver Consensus Guidelines. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2012, 26, 917-938.	1.8	60
129	Case report: Management and HBV sequencing in a patient co-infected with HBV and HIV failing tenofovir. <i>Journal of Medical Virology</i> , 2012, 84, 1340-1343.	2.5	7
130	Long-term outcome of primary non-responders to tenofovir therapy in HIV/ HBV co-infected patients: impact of HBV genotype G. <i>Liver International</i> , 2012, 32, 93-101.	1.9	16
131	Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B mono-infection. <i>Hepatology International</i> , 2013, 7, 327-334.	1.9	3
132	Polymerase mutations rtN238R, rtT240Y and rtN248H of hepatitis B virus decrease susceptibility to adefovir. <i>Science Bulletin</i> , 2013, 58, 1760-1766.	1.7	7
133	Hepatitis B in HIV-Infected Patients. <i>Clinics in Liver Disease</i> , 2013, 17, 489-501.	1.0	24
134	Virology and clinical sequelae of long-term antiviral therapy in a North American cohort of hepatitis B virus (HBV)/human immunodeficiency virus type 1 (HIV-1) co-infected patients. <i>Journal of Clinical Virology</i> , 2013, 57, 103-108.	1.6	35
135	The amino acid substitutions rtP177G and rtF249A in the reverse transcriptase domain of hepatitis B virus polymerase reduce the susceptibility to tenofovir. <i>Antiviral Research</i> , 2013, 97, 93-100.	1.9	44
136	Hepatitis B virus reverse transcriptase mutations in treatment-naïve chronic hepatitis B patients. <i>Journal of Medical Virology</i> , 2013, 85, 1155-1162.	2.5	17
137	High incidence of treatment-induced and vaccine-escape hepatitis B virus mutants among human immunodeficiency virus/hepatitis B-infected patients. <i>Hepatology</i> , 2013, 58, 912-922.	3.6	37
138	HIV/HBV coinfection in children and antiviral therapy. <i>Expert Review of Anti-Infective Therapy</i> , 2013, 11, 251-263.	2.0	16
139	Efficacy of Tenofovir in Patients with Lamivudine Failure Is Not Different from That in Nucleoside/Nucleotide Analogue-Naïve Patients with Chronic Hepatitis B. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 1790-1796.	1.4	37
140	Substitution Rtq267h of Hepatitis B Virus Increases the Weight of Replication and Lamivudine Resistance. <i>Hepatitis Monthly</i> , 2013, 13, e12160.	0.1	5
141	Patterns and Causes of Suboptimal Response to Tenofovir-Based Therapy in Individuals Coinfected With HIV and Hepatitis B Virus. <i>Clinical Infectious Diseases</i> , 2013, 56, e87-e94.	2.9	69

#	ARTICLE	IF	CITATIONS
142	HIV and HBV Coinfection in Southern Africa and the Effect of Lamivudine- Versus Tenofovir-Containing cART on HBV Outcomes. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2013, 64, 174-182.	0.9	53
143	Virologic breakthrough in a patient with chronic hepatitis B by combination treatment with tenofovir disoproxil fumarate and entecavir. <i>Drug Design, Development and Therapy</i> , 2014, 8, 869.	2.0	9
144	Current developments in nucleoside/nucleotide analogues for hepatitis B. <i>Expert Review of Gastroenterology and Hepatology</i> , 2014, 8, 607-622.	1.4	36
145	Mechanisms of Hepatitis B Virus Resistance Development. <i>Intervirology</i> , 2014, 57, 218-224.	1.2	22
146	Management and treatment of chronic hepatitis B in HIV-positive patients. <i>Annals of Medicine</i> , 2014, 46, 290-296.	1.5	11
147	Clinical implications of hepatitis B virus mutations: Recent advances. <i>World Journal of Gastroenterology</i> , 2014, 20, 7653.	1.4	120
148	High-Throughput Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry as an Alternative Approach to Monitoring Drug Resistance of Hepatitis B Virus. <i>Journal of Clinical Microbiology</i> , 2014, 52, 9-14.	1.8	10
149	Viral evolutionary changes during tenofovir treatment in a chronic hepatitis B patient with sequential nucleos(t)ide therapy. <i>Journal of Clinical Virology</i> , 2014, 60, 313-316.	1.6	21
150	Nucleoside/nucleotide analog inhibitors of hepatitis B virus polymerase: mechanism of action and resistance. <i>Current Opinion in Virology</i> , 2014, 8, 1-9.	2.6	131
151	Amino acid similarities and divergences in the small surface proteins of genotype C hepatitis B viruses between nucleos(t)ide analogue-naïve and lamivudine-treated patients with chronic hepatitis B. <i>Antiviral Research</i> , 2014, 102, 29-34.	1.9	18
152	An HBV-HIV Co-infected Patient Treated with Tenofovir-based Therapy who Achieved HBs Antigen/Antibody Seroconversion. <i>Internal Medicine</i> , 2014, 53, 1343-1346.	0.3	0
153	Management of chronic hepatitis B infection: Current treatment guidelines, challenges, and new developments. <i>World Journal of Gastroenterology</i> , 2014, 20, 6262.	1.4	111
154	Factors Associated With Delayed Hepatitis B Viral Suppression on Tenofovir Among Patients Coinfected With HBV-HIV in the CNICS Cohort. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2014, 66, 96-101.	0.9	23
155	Tenofovir-based rescue therapy in chronic hepatitis B patients with suboptimal responses to adefovir with prior lamivudine resistance. <i>Journal of Medical Virology</i> , 2015, 87, 1532-1538.	2.5	10
156	Chronic Hepatitis B with Spontaneous Severe Acute Exacerbation. <i>International Journal of Molecular Sciences</i> , 2015, 16, 28126-28145.	1.8	15
158	Advances in treating drug-resistant hepatitis B virus in HIV-infected patients. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 179-186.	0.9	7
159	Emerging Challenges in Managing Hepatitis B in HIV Patients. <i>Current HIV/AIDS Reports</i> , 2015, 12, 344-352.	1.1	23
160	Molecular mechanisms underlying HBsAg negativity in occult HBV infection. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2015, 34, 1709-1731.	1.3	21

#	ARTICLE	IF	CITATIONS
161	Unveiling the roles of HBV polymerase for new antiviral strategies. <i>Future Virology</i> , 2015, 10, 283-295.	0.9	36
162	Response to potent anti-HBV agents in chronic hepatitis B and combined effect of HBV reverse transcriptase mutations. <i>Gene</i> , 2015, 567, 22-30.	1.0	1
163	Efficacy of tenofovir switch therapy for nucleos(t)ide-experienced patients with chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 1190-1199.	1.9	7
164	Monotherapy for hepatitis B infection: a review of treatment options. <i>Expert Review of Anti-Infective Therapy</i> , 2015, 13, 1457-1468.	2.0	7
165	Hepatitis B Virus. , 2016, , 713-770.		2
166	KASL clinical practice guidelines: management of chronic hepatitis B. <i>Clinical and Molecular Hepatology</i> , 2016, 22, 18-75.	4.5	155
167	Treatment for hepatitis B in patients with drug resistance. <i>Annals of Translational Medicine</i> , 2016, 4, 334-334.	0.7	22
168	The Safety of Tenofovir+Emtricitabine for HIV Pre-Exposure Prophylaxis (PrEP) in Individuals With Active Hepatitis B. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 71, 281-286.	0.9	25
169	Small surface antigen variants of HBV associated with responses to telbivudine treatment in chronic hepatitis B patients. <i>Antiviral Therapy</i> , 2016, 22, 43-51.	0.6	2
170	Nucleos(t)ide analogues causes HBV S gene mutations and carcinogenesis. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2016, 15, 579-586.	0.6	16
171	Overview of hepatitis B viral replication and genetic variability. <i>Journal of Hepatology</i> , 2016, 64, S4-S16.	1.8	303
172	Evaluation of HBV resistance to tenofovir in patients with chronic hepatitis B using ZNA probe assay in Kerman, southeast of Iran. <i>Asian Pacific Journal of Tropical Disease</i> , 2016, 6, 513-516.	0.5	1
173	Evidence of susceptibility to lamivudine-based HAART and genetic stability of hepatitis B virus (HBV) in HIV co-infected patients: A South African longitudinal HBV whole genome study. <i>Infection, Genetics and Evolution</i> , 2016, 43, 232-238.	1.0	5
174	A novel method for nucleos(t)ide analogues susceptibility assay of hepatitis B virus by viral polymerase transcomplementation. <i>Antiviral Research</i> , 2016, 126, 99-107.	1.9	1
175	Molecular characterization of hepatitis B virus from chronically-infected patients in Niamey, Niger. <i>International Journal of Infectious Diseases</i> , 2016, 45, 18-23.	1.5	8
176	Effect of tenofovir disoproxil fumarate on drug-resistant HBV clones. <i>Journal of Infection</i> , 2016, 72, 91-102.	1.7	17
177	Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. <i>Hepatology International</i> , 2016, 10, 1-98.	1.9	1,908
178	Selection of the highly replicative and partially multidrug resistant rtS78T HBV polymerase mutation during TDF-ETV combination therapy. <i>Journal of Hepatology</i> , 2017, 67, 246-254.	1.8	52

#	ARTICLE	IF	CITATIONS
179	New antivirals for the treatment of chronic hepatitis B. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 843-851.	1.9	43
180	HIV-hepatitis B virus coinfection. <i>Aids</i> , 2017, 31, 2035-2052.	1.0	171
181	Management of hepatitis B in special populations. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2017, 31, 311-320.	1.0	24
182	Efficacy of long-term tenofovir-based rescue therapy in patients with chronic hepatitis B refractory to nucleoside/nucleotide analogs. <i>Journal of Gastroenterology</i> , 2017, 52, 641-651.	2.3	15
183	Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. <i>Hepatology</i> , 2018, 67, 1560-1599.	3.6	2,620
184	Treatment of HCV, HDV, or HIV Coinfection. , 2018, , 239-262.		2
185	Nucleos(t)ide Therapy and Long-Term Outcomes. , 2018, , 193-217.		1
186	2-Fluoro-2-methylene carbocyclic adenosine and its phosphoramidate prodrug: A novel anti-HBV agent active against drug-resistant HBV mutants. <i>Medicinal Research Reviews</i> , 2018, 38, 977-1002.	5.0	12
187	Molecular Virology and Life Cycle. , 2018, , 1-23.		1
188	Development of tenofovir disoproxil fumarate resistance after complete viral suppression in a patient with treatment-naïve chronic hepatitis B: A case report and review of the literature. <i>World Journal of Gastroenterology</i> , 2018, 24, 1919-1924.	1.4	20
189	A systematic review of hepatitis B virus (HBV) drug and vaccine escape mutations in Africa: A call for urgent action. <i>PLoS Neglected Tropical Diseases</i> , 2018, 12, e0006629.	1.3	55
190	KASL clinical practice guidelines for management of chronic hepatitis B. <i>Clinical and Molecular Hepatology</i> , 2019, 25, 93-159.	4.5	171
191	Locus 5p13.1 may be associated with the selection of cancer-related HBV core promoter mutations. <i>International Journal of Medical Sciences</i> , 2019, 16, 990-997.	1.1	0
192	Screening for retroviruses and hepatitis viruses using dried blood spots reveals a high prevalence of occult hepatitis B in Ghana. <i>Therapeutic Advances in Infectious Disease</i> , 2019, 6, 204993611985146.	1.1	7
193	Potential resistant mutations within HBV reverse transcriptase sequences in nucleos(t)ide analogues-experienced patients with hepatitis B virus infection. <i>Scientific Reports</i> , 2019, 9, 8078.	1.6	18
194	<p></p>Current progress in the prevention of mother-to-child transmission of hepatitis B and resulting clinical and programmatic implications</p>. <i>Infection and Drug Resistance</i> , 2019, Volume 12, 977-987.	1.1	5
195	2018 Korean Association for the Study of the Liver (KASL) Clinical Practice Guidelines of Chronic Hepatitis B: What's Different?. <i>Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The</i> , 2019, 73, 132.	0.2	5
196	Viral quasispecies of hepatitis B virus in patients with YMDD mutation and lamivudine resistance may not predict the efficacy of lamivudine/adefovir rescue therapy. <i>Experimental and Therapeutic Medicine</i> , 2019, 17, 2473-2484.	0.8	5

#	ARTICLE	IF	CITATIONS
197	Identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients. <i>Journal of Hepatology</i> , 2019, 70, 1093-1102.	1.8	107
198	HBV Infection in HIV-Driven Immune Suppression. <i>Viruses</i> , 2019, 11, 1077.	1.5	26
199	Taiwan consensus statement on the management of chronic hepatitis B. <i>Journal of the Formosan Medical Association</i> , 2019, 118, 7-38.	0.8	64
200	Nanopore sequencing from extraction-free direct PCR of dried serum spots for portable hepatitis B virus drug-resistance typing. <i>Journal of Clinical Virology</i> , 2020, 129, 104483.	1.6	9
201	Epidemiology, Natural History, and Treatment of Hepatitis Delta Virus Infection in HIV/Hepatitis B Virus Coinfection. <i>Current HIV/AIDS Reports</i> , 2020, 17, 405-414.	1.1	22
202	Japan Society of Hepatology Guidelines for the Management of Hepatitis B Virus Infection: 2019 update. <i>Hepatology Research</i> , 2020, 50, 892-923.	1.8	66
203	Characterization of Hepatitis B virus polymerase mutations A194T and CYEI and tenofovir disoproxil fumarate or tenofovir alafenamide resistance. <i>Journal of Viral Hepatitis</i> , 2021, 28, 30-39.	1.0	10
204	In vitro Study on Synergistic Interactions Between Free and Encapsulated Q-Griffithsin and Antiretrovirals Against HIV-1 Infection. <i>International Journal of Nanomedicine</i> , 2021, Volume 16, 1189-1206.	3.3	8
205	The Occurrence of rtA194T Mutant After Long-Term Lamivudine Monotherapy Remains Sensitive to Tenofovir Disoproxil Fumarate: A Case Report. <i>Infection and Drug Resistance</i> , 2021, Volume 14, 1013-1017.	1.1	2
206	Molecular and computational analysis of natural drug resistance mutations among Moroccan chronic hepatitis B carriers. <i>Gene Reports</i> , 2021, 23, 101197.	0.4	0
207	Current laboratory tests for diagnosis of hepatitis B virus infection. <i>International Journal of Clinical Practice</i> , 2021, 75, e14812.	0.8	6
208	Nucleos(t)ide Therapy and Long-Term Outcomes. , 2021, , 287-318.		0
211	Hepatitis Virus Resistance. , 2008, , 291-323.		2
212	The Hepatitis B Virus and Antiviral Drug Resistance: Causes, Patterns, and Mechanisms. , 2009, , 519-530.		1
213	Hepatitis B Virus Drug Resistance. , 2017, , 1227-1242.		10
216	An initial assessment of correlations between host- and virus-related factors affecting antiviral therapy in HBV chronically infected patients. <i>Medical Science Monitor</i> , 2014, 20, 321-328.	0.5	4
217	Hepatitis B virus resistance to tenofovir: fact or fiction? A systematic literature review and structural analysis of drug resistance mechanisms. <i>Wellcome Open Research</i> , 2020, 5, 151.	0.9	10
218	Suppression of HBV by Tenofovir in HBV/HIV Coinfected Patients: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2013, 8, e68152.	1.1	75

#	ARTICLE	IF	CITATIONS
219	Hepatitis B Infection, Viral Load and Resistance in HIV-Infected Patients in Mozambique and Zambia. PLoS ONE, 2016, 11, e0152043.	1.1	25
220	The Molecular and Structural Basis of HBV-resistance to Nucleos(t)ide Analogs. Journal of Clinical and Translational Hepatology, 2014, 2, 202-11.	0.7	20
221	Diagnosis and monitoring of chronic viral hepatitis serologic and molecular markers. Frontiers in Bioscience - Scholar, 2011, S3, 156-167.	0.8	3
222	KASL Clinical Practice Guidelines: Management of chronic hepatitis B. Clinical and Molecular Hepatology, 2012, 18, 109.	4.5	143
223	Options for the management of antiviral resistance during hepatitis B therapy: reflections on battles over a decade. Clinical and Molecular Hepatology, 2013, 19, 195.	4.5	27
225	Hepatitis B virus mutations potentially conferring adefovir/tenofovir resistance in treatment-naive patients. World Journal of Gastroenterology, 2009, 15, 753.	1.4	33
226	Future prospectives for the management of chronic hepatitis B. World Journal of Gastroenterology, 2007, 13, 2554.	1.4	23
227	Low-dose tenofovir is more potent than adefovir and is effective in controlling HBV viremia in chronic HBeAg-negative hepatitis B. World Journal of Gastroenterology, 2007, 13, 4096.	1.4	23
228	Current therapeutic strategies for recurrent hepatitis B virus infection after liver transplantation. World Journal of Gastroenterology, 2010, 16, 2468.	1.4	14
229	Diagnostic and therapeutic progress of multi-drug resistance with anti-HBV nucleos(t)ide analogues. World Journal of Gastroenterology, 2012, 18, 7149.	1.4	19
230	Quasispecies structure, cornerstone of hepatitis B virus infection: Mass sequencing approach. World Journal of Gastroenterology, 2013, 19, 6995.	1.4	35
231	Management of antiviral drug resistance in chronic hepatitis B. World Journal of Gastroenterology, 2014, 20, 11641.	1.4	21
232	Current Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B. Gut and Liver, 2011, 5, 278-287.	1.4	22
233	Update of treatment for chronic hepatitis B using nucleos(t)ide analogues. Acta Hepatologica Japonica, 2006, 47, 499-502.	0.0	1
234	Treatment of Hepatitis B in HIV-Infected Persons. , 2012, , 141-149.		0
236	Tenofovir therapy in chronic hepatitis B infection: 48-week results from Izmir Province, Turkey. Journal of Microbiology and Infectious Diseases, 2012, 2, 87-92.	0.1	0
237	Mechanisms of Resistance to Antiviral Agents. , 0, , 1894-1912.		3
238	Treatment of Hepatitis B. , 2018, , 485-500.e5.		0

#	ARTICLE	IF	CITATIONS
239	Successful Management of a Patient with Multiple Nucleos(t)ide Analogue-Resistant Hepatitis B Virus and Diffuse Large B Cell Lymphoma Using Tenofovir Disoproxil Fumarate: A Case Report. Journal of the Nihon University Medical Association, 2019, 78, 295-300.	0.0	0
240	Persistent Hepatitis B Viraemia with Polymerase Mutations among HIV/HBV Co-Infected Patients on HBV-Active ART in KwaZulu-Natal, South Africa. Viruses, 2022, 14, 788.	1.5	3
241	Major Causes of Antiviral drug Resistance and Implications for Treatment of Hepatitis B virus Mono-infection and Co-infection with HIV. Antiviral Therapy, 2007, 12, 15-23.	0.6	71
242	Special Considerations and Treatment of Patients with HBV-HIV Coinfection. Antiviral Therapy, 2007, 12, 43-51.	0.6	6
243	Comparison of the antiviral activity of adefovir and tenofovir on hepatitis B virus in HIV-coinfected patients. Antiviral Therapy, 2008, 13, 705-713.	0.6	21
244	The pathogenesis of liver disease in the setting of HIV-hepatitis B virus coinfection. Antiviral Therapy, 2009, 14, 155-164.	0.6	18
245	Characterization of the tenofovir resistance-associated mutations in the hepatitis B virus isolates across genotypes A to D. Antiviral Research, 2022, 203, 105348.	1.9	3
246	Improvements in Parameters of End-Stage Liver Disease in Patients with HIV/HBV-related Cirrhosis Treated with Tenofovir. Antiviral Therapy, 2007, 12, 119-122.	0.6	31